Skip to main content

Table 5 Evaluation of risk of bias in the included studies

From: Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Items

PointBreak 2013

AVAPERL 2014

ERACLE 2015

PRONOUNCE 2015

COMPASS 2019

EA5508

2019

Randomization sequence generation

low

low

low

low

low

low

Allocation concealment

unclear

unclear

unclear

unclear

unclear

unclear

Blinding of participants and personnel

high

high

unclear

high

unclear

high

Blinding of outcome assessment

high

high

unclear

high

unclear

unclear

Incomplete outcome data

high

low

high

low

unclear

low

Selective reporting

unclear

unclear

low

low

low

low

Other biases

low

unclear

low

low

unclear

low